Arndt Borkhardt

43.2k total citations · 1 hit paper
342 papers, 10.2k citations indexed

About

Arndt Borkhardt is a scholar working on Molecular Biology, Public Health, Environmental and Occupational Health and Hematology. According to data from OpenAlex, Arndt Borkhardt has authored 342 papers receiving a total of 10.2k indexed citations (citations by other indexed papers that have themselves been cited), including 115 papers in Molecular Biology, 106 papers in Public Health, Environmental and Occupational Health and 100 papers in Hematology. Recurrent topics in Arndt Borkhardt's work include Acute Lymphoblastic Leukemia research (95 papers), Acute Myeloid Leukemia Research (57 papers) and Childhood Cancer Survivors' Quality of Life (44 papers). Arndt Borkhardt is often cited by papers focused on Acute Lymphoblastic Leukemia research (95 papers), Acute Myeloid Leukemia Research (57 papers) and Childhood Cancer Survivors' Quality of Life (44 papers). Arndt Borkhardt collaborates with scholars based in Germany, United States and Austria. Arndt Borkhardt's co-authors include Jochen Harbott, Thomas Tuschl, Uta Fuchs, Reinald Repp, Jutta Meyer, Reinhard Rauhut, Mariana Lagos‐Quintana, Susanne Viehmann, Michaela Kuhlen and Martin Schrappe and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Arndt Borkhardt

323 papers receiving 10.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

New microRNAs from mouse and human

2003 703 citations Arndt Borkhardt et al. profile →

Peers

Countries citing papers authored by Arndt Borkhardt

Since Specialization

Citations

This map shows the geographic impact of Arndt Borkhardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arndt Borkhardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arndt Borkhardt more than expected).

Fields of papers citing papers by Arndt Borkhardt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arndt Borkhardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arndt Borkhardt. The network helps show where Arndt Borkhardt may publish in the future.

Co-authorship network of co-authors of Arndt Borkhardt

This figure shows the co-authorship network connecting the top 25 collaborators of Arndt Borkhardt. A scholar is included among the top collaborators of Arndt Borkhardt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arndt Borkhardt. Arndt Borkhardt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Trajectories from single-cells to PAX5-driven leukemia reveal PAX5-MYC interplay in vivo 2025 ·Leukemia ·Franziska Auer, (unknown), (unknown), (unknown), (unknown), Julie Vogt, (unknown), (unknown), (unknown), Andrea Hänel, Anna Viitasalo, Ulrike Friedrich, Andreas Dahl, (unknown), Aleksandra A. Pandyra, Polina Stepensky, Masatoshi Takagi, Arndt Borkhardt, (unknown), Julia Hauer	1
2	Osteosarcoma as a secondary malignancy following rhabdomyosarcoma: A report of 28 affected patients from the Cooperative Osteosarcoma Study Group (COSS) 2024 ·Pediatric Blood & Cancer ·Stefan Bielack, (unknown), Stefanie Hecker‐Nolting, Arndt Borkhardt, Jendrik Hardes, Leo Kager, Thekla von Kalle, Matthias Kevric, Ewa Kościelniak, Christian P. Kratz, Thomas Kühne, Michaela Nathrath, Claudia Rössig, Benjamin Sorg, Monika Sparber‐Sauer, Mathias Werner, Claudia Blattmann	1
3	Hyperdiploid acute lymphoblastic leukemia in children with LZTR1 germline variants 2024 ·HemaSphere ·(unknown), Rabea Wagener, Ute Fischer, Anna Hoffmann, (unknown), (unknown), (unknown), (unknown), Carolin Walter, Julian Varghese, Julia Hauer, Franziska Auer, Sanil Bhatia, Martin Dugas, Stefanie V. Junk, Martin Stanulla, Oskar A. Haas, Arndt Borkhardt, Tobias Reiff, Triantafyllia Brozou	2
4	Pediatric Patients with Stage IV Rhabdomyosarcoma Significantly Benefit from Long-Term Maintenance Therapy: Results of the CWS-IV 2002 and the CWS DOK IV 2004-Trials 2023 ·Cancers ·Lars Tramsen, Konrad Bochennek, Monika Sparber‐Sauer, Emilia Salzmann‐Manrique, Monika Scheer, Tobias M. Dantonello, Arndt Borkhardt, Uta Dirksen, Anne Thorwarth, Jeanette Greiner, Martin Ebinger, (unknown), Ruth Ladenstein, Gustaf Ljungman, Erika Hallmen, Thomas Lehrnbecher, Ewa Kościelniak, Thomas Klingebiel	13
5	Temporal patterns of childhood cancer survival 1991 to 2016: A nationwide register‐study based on data from the German Childhood Cancer Registry 2023 ·International Journal of Cancer ·(unknown), Claudia Spix, Cécile M. Ronckers, Desiree Grabow, (unknown), Arndt Borkhardt, Daniel Wollschläger, Friederike Erdmann	9
6	A clinical screening tool to detect genetic cancer predisposition in pediatric oncology shows high sensitivity but can miss a substantial percentage of affected children 2023 ·Genetics in Medicine ·Ulrike Friedrich, (unknown), (unknown), (unknown), (unknown), Arne Jahn, (unknown), (unknown), Carolin Walter, Rabea Wagener, Triantafyllia Brozou, Julian Varghese, Martin Dugas, Miriam Erlacher, Evelin Schröck, Meinolf Suttorp, Arndt Borkhardt, Julia Hauer, Franziska Auer	2
7	High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia 2023 ·Biochemical Pharmacology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Angela Maria Savino, Daniela Silvestri, Maria Grazia Valsecchi, Andrea Biondi, Arndt Borkhardt, Sanil Bhatia, Giovanni Cazzaniga, Grazia Fazio, Michela Bardini, Chiara Palmi	11
8	Consensus Recommendations for the Clinical Management of Hematological Malignancies in Patients with DNA Double Stranded Break Disorders 2022 ·Cancers ·Agata Pastorczak, Andishe Attarbaschi, Simon Bomken, Arndt Borkhardt, Jutte van der Werff ten Bosch, Sarah Elitzur, Andrew R. Gennery, Eva Hlaváčková, (unknown), Zdenka Křenová, Wojciech Młynarski, Tomasz Szczepański, Tessa Wassenberg, Jan Loeffen	11
9	Hyperdiploidy: the longest known, most prevalent, and most enigmatic form of acute lymphoblastic leukemia in children 2022 ·Leukemia ·Oskar A. Haas, Arndt Borkhardt	16
10	The Microbiome in Childhood Acute Lymphoblastic Leukemia 2021 ·Cancers ·Marina Oldenburg, Nadine Rüchel, Stefan Janssen, Arndt Borkhardt, Katharina L. Gössling	19
11	4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads 2021 ·Journal of Medicinal Chemistry ·Linda Schäker‐Hübner, (unknown), (unknown), Pankaj Mishra, (unknown), (unknown), Andrea Schöler, Arndt Borkhardt, Bernhard Breit, Sanil Bhatia, (unknown), Stefan Günther, Finn K. Hansen	31
12	QRICH1 variants in Ververi‐Brady syndrome—delineation of the genotypic and phenotypic spectrum 2020 ·Clinical Genetics ·(unknown), Rami Abou Jamra, Arndt Borkhardt, Triantafyllia Brozou, Petra Muschke, Bernt Popp, (unknown), Jörg Schaper, Harald Surowy, Martin Zenker, Christiane Zweier, Dagmar Wieczorek, Silke Redler	6
13	Discovery of the First-in-Class Dual Histone Deacetylase–Proteasome Inhibitor 2018 ·Journal of Medicinal Chemistry ·Sanil Bhatia, (unknown), M. Groll, J.D. Osko, Nina Reßing, (unknown), Arndt Borkhardt, Thomas Kurz, David W. Christianson, Julia Hauer, Finn K. Hansen	62
14	Homozygous HOXB1 loss‐of‐function mutation in a large family with hereditary congenital facial paresis 2016 ·American Journal of Medical Genetics Part A ·Markus Vogel, Eunike Velleuer, (unknown), Ertan Mayatepek, Arndt Borkhardt, Malik Alawi, Kerstin Kutsche, Fanny Kortüm	21
15	Mouse models for pre-clinical drug testing in leukemia 2016 ·Expert Opinion on Drug Discovery ·Sanil Bhatia, Svenja Daschkey, Franziska Lang, Arndt Borkhardt, Julia Hauer	4
16	Early-onset Evans syndrome, immunodeficiency, and premature immunosenescence associated with tripeptidyl-peptidase II deficiency 2014 ·Blood ·Polina Stepensky, Anne Rensing‐Ehl, (unknown), Shoshana Revel‐Vilk, Ute Fischer, Schafiq Nabhani, Fabian Beier, Tim H. Brümmendorf, Sebastian Fuchs, (unknown), Elke Firat, (unknown), Arndt Borkhardt, Mirzokhid Rakhmanov, Bärbel Keller, Klaus Warnatz, Hermann Eibel, Gabriele Niedermann, Orly Elpeleg, Stephan Ehl	57
17	Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group 2008 ·Journal of Clinical Oncology ·Peter Bader, Hermann Kreyenberg, Günter Henze, Cornelia Eckert, (unknown), André Willasch, Andrea Barth, Arndt Borkhardt, Christina Peters, Rupert Handgretinger, Karl‐Walter Sykora, Wolfgang Holter, H. Kabisch, Thomas Klingebiel, Arend von Stackelberg	252
18	NQO1 C609T polymorphism in distinct entities of pediatric hematologic neoplasms. 2004 ·PubMed ·(unknown), Martin Schrappe, Sabine Strehl, Alfred Reiter, Holger-Andreas Elsner, Jan Trka, Gunnar Cario, Susanne Viehmann, Jochen Harbott, Arndt Borkhardt, Markus Metzler, Thorsten Langer, Reinald Repp, Rolf Marschalek, Karl Welte, Oskar A. Haas, Martin Stanulla	29
19	Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. 1996 ·PubMed ·(unknown), Arndt Borkhardt, (unknown), J. Ritterbach, Johannes W.G. Janssen, Richard Ratei, Martin Schrappe, Reinald Repp, M Zimmermann, H. Kabisch, G. Janka‐Schaub, CR Bartram, Wolfgang Ludwig, H. Riehm, F. Lampert, Jochen Harbott	103
20	A novel type of MLL/AF10 fusion transcript in a child with acute megakaryocytic leukemia (AML-M7) 1995 ·PubMed ·Arndt Borkhardt, (unknown), Wolfgang Strobl, Roland Repp, Georg Mann, Helmut Gadner, F. Lampert	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact